H100 is shown to be effective with statistically significant improvement in penile curvature, stretched penile length, and pain. H100 topical gel is noninvasive. These conclusions are the result of a prior placebo-controlled trial published in a peer reviewed journal (IJIR): “Topical Treatment of Acute Phase Peyronie’s Disease Utilizing a New Gel, H100: A Randomized, Prospective, Placebo-Controlled Pilot Study”.
Despite the favorable results seen in the original H100 study, the article “Transdermal Application of H100 Gel to the Penile Shaft in Patients with Peyronie’s Disease Infiltrates the Tunica Albuginea” needed to answer the very important question, “Does H100 actually infiltrate the tunica albuginea?”. The answer is an unequivocal “Yes”. Confirmation of tunica albuginea infiltration of H100 is important because prior transdermal therapies for PD failed to show consistent efficacy and also failed to demonstrate tunica albuginea infiltration.
Hybrid Medical’s H100™ may prove to be the first effective, noninvasive, topical treatment for Peyronie’s disease. Penile traction or stretching exercises are recommended in combination with H100 use for best results. Further studies are needed to better define the optimal therapeutic concentration and duration of treatment needed for best results. H100 is commercially available via prescription through PD Labs (pdlabsrx.com).
Written by: Jeffry Twidwell, MD, Minnesota Urology, Minneapolis, MN, USA.
Read the Abstract